ReviewVeterinary sciences2026
NMR Metabolomics in Veterinary Medicine: From Biomarker Discovery to Clinical Implementation.
Review in Veterinary sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Nuclear magnetic resonance (NMR)-based metabolomics has emerged as a robust and reproducible analytical platform for investigating the molecular mechanisms underlying disease and identifying candidate biomarkers with potential clinical relevance. Although initially developed for biomedical research, its application in veterinary medicine has expanded rapidly during the last decade, driven by the growing demand for precision medicine approaches capable of improving disease diagnosis, prognosis and therapeutic monitoring. This review summarizes the current landscape of NMR metabolomics in veterinary medicine, highlighting its applications across major clinical areas, including oncology, infectious, respiratory, digestive, renal, endocrine and musculoskeletal diseases. Collectively, the available evidence demonstrates that NMR metabolomics consistently identifies disease-associated metabolic alterations, providing novel insights into pathophysiology while supporting biomarker discovery in naturally occurring animal diseases. Beyond current clinical applications, we discuss the major challenges that continue to limit routine implementation, including biological variability, standardization of analytical workflows, multicentre validation and clinical translation. Particular attention is given to recent technological advances, such as benchtop NMR instrumentation, artificial intelligence-assisted data analysis, multi-omics integration and the development of collaborative networks and standardized platforms. Together, these advances position NMR metabolomics as a promising technology to support precision veterinary medicine, facilitating its transition from biomarker discovery to routine clinical implementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.